Antithrombotic therapy in acute coronary syndromes: which agent and when? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino [email protected].
CHARISMA Genomics Deepak L. Bhatt MD, MPH, Katy L. Simonsen PhD, Eileen S. Emison PhD, Keith A. A. Fox MBChB, P. Gabriel Steg MD, Gilles Montalescot MD,
Antiplatelet response to aspirin and clopidogrel in patients with coronary artery disease undergoing percutaneous coronary intervention
Mark W Linder, Ph.D., DABCC, FACB Medical Director, EVP Operations Kristen K. Reynolds Ph.D. Associate Medical Director, VP Laboratory Operations Mark.
Kristen K. Reynolds, PhD Associate Medical Director, VP Laboratory Operations Copyright 2010 PGXL Laboratories LLC, Louisville KY All materials herein.
Literature Review
Optimal Angioplasty Pharmacology in 2006 : is there a continuing need for GP IIbIIIa inhibitors?
